CF
LENZ

Cantor Fitzgerald’s LENZ Therapeutics LENZ Stock Holding History

Cantor Fitzgerald’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,286
Closed -$275K – 861
2022
Q2 		$275K Buy
+14,286
New +$318K 0.01% 621

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cantor Fitzgerald's LENZ Position: Q3 2022 in Review

Cantor Fitzgerald sold out of LENZ Therapeutics (LENZ) in Q3 2022, closing a stake of 14,286 shares — an estimated $275K sold.

Cantor Fitzgerald first reported a position in LENZ in Q2 2022 and held it in 1 quarter. The position peaked at $275K in Q2 2022. 63 funds tracked by Wall St. Rank hold LENZ as of Q3 2022.

  • Cantor Fitzgerald reported no remaining LENZ Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cantor Fitzgerald sold 14,286 LENZ Therapeutics shares in Q3 2022, an estimated $275K.
  • Cantor Fitzgerald first reported a position in LENZ Therapeutics in Q2 2022 and held it in 1 quarter.
  • Cantor Fitzgerald's LENZ Therapeutics position peaked at $275K in Q2 2022.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2022.

Based on Cantor Fitzgerald's 13F filing for Q3 2022, filed 14 Nov 2022.